Early Adverse Events detection and characterization
Identification of surrogate Endpoints
Design of new Composite Efficacy/Safety Endpoints
The decision support provided by KEM® helps expedite product registration; it can also be used for effective product repositioning
How does KEM® bring added value to Clinical Trials Strategies?
By leveraging clinical trials productivity thanks to early identification of protocol bias to avoid clinical study failure.
By optimizing Benefit/Risk ratio through exhaustive responder analysis and characterizing populations at baseline which are either more responsive or at risk.
